EUVIMEDEUVIMED entdecken
Crossref

Benzimidazole Derivatives as Potential Inhibitors of Monkeypox A41 Protein: DFT Calculations, Molecular Docking, ADME, and Toxicity Assessments

Nuaman F. Alheety, Ahmed A. Al‐Kubaisi, Enrico Benassi, Noureddine Raouafi, Chayma Ben Maamer, Mustafa A. Alheety, Rafâa Besbes

ChemistrySelect · 2025-07 · 10 (27)

DOI: 10.1002/slct.202501475 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemistrySelect, online erschienen am 18.07.2025. Verfasst von Nuaman F. Alheety und 6 weiteren Autor:innen. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 65 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of monkeypox virus (Mpox) infection poses a significant and worrying danger to the human world. The absence of pharmaceutical compounds to treat the disease might make the problems worse. Identifying prospective pharmacological targets may greatly enhance the process of generating highly effective chemical molecules for the treatment of the Mpox virus. In this study, five new benzimidazole derivatives ( 1a‐e ) were synthesized and characterized using FT‐IR and 1 H‐NMR. Quantum chemical calculations at the density functional theory (DFT) level were performed on compounds ( 1a‐e ) and on Tecovirimat ( 2 ), used as a reference molecule, to compute the most stable molecular conformation and its electrostatic and electronic properties. Molecular docking studies revealed that the effectiveness of compounds ( 1a‐e ) is comparable to that of Tecovirimat ( 2 ), an FDA‐approved antiviral molecule against the Mpox virus, responsible for many side effects. The interaction of 1c compound with protein 8JC6 causes the most negative binding energy (−6.017 kcal/mol), while the calculated value for 2 compound is −5.442 kcal/mol. Other compounds ( 1a , 1b , 1d , and 1e ) show a good binding energy for 8JC6 (−5.206, −5.825, −5.682, and −5.855 kcal/mol, respectively). Pharmacokinetics and toxicity analysis also revealed good antiviral candidacy of these compounds, which may therefore be recommended as new antiviral agents to combat the Mpox virus.

Zitieren

APA

Alheety, N. F., Al‐Kubaisi, A. A., Benassi, E., Raouafi, N., Maamer, C. B., Alheety, M. A., & Besbes, R. (2025). Benzimidazole Derivatives as Potential Inhibitors of Monkeypox A41 Protein: DFT Calculations, Molecular Docking, ADME, and Toxicity Assessments. ChemistrySelect, 10(27). https://doi.org/10.1002/slct.202501475

Vancouver

Alheety NF, Al‐Kubaisi AA, Benassi E, Raouafi N, Maamer CB, Alheety MA, et al. Benzimidazole Derivatives as Potential Inhibitors of Monkeypox A41 Protein: DFT Calculations, Molecular Docking, ADME, and Toxicity Assessments. ChemistrySelect. 2025;10(27). doi:10.1002/slct.202501475

BibTeX
@article{Alheety2025,
  author = {Alheety, Nuaman F. and Al‐Kubaisi, Ahmed A. and Benassi, Enrico and Raouafi, Noureddine and Maamer, Chayma Ben and Alheety, Mustafa A. and Besbes, Rafâa},
  title = {Benzimidazole Derivatives as Potential Inhibitors of Monkeypox A41 Protein: DFT Calculations, Molecular Docking, ADME, and Toxicity Assessments},
  journal = {ChemistrySelect},
  year = {2025},
  volume = {10},
  number = {27},
  doi = {10.1002/slct.202501475}
}
Kostenlos starten →